Solid Biosciences Inc. Operating Lease, Weighted Average Discount Rate, Percent
Solid Biosciences Inc. (SLDB) had Operating Lease, Weighted Average Discount Rate, Percent of 10.80% as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-19
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.80%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.80%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.70%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.60%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2025-12-31 | 10.80% 10-K · filed 2026-03-19 |
| 2024-12-31 | 10.80% 10-K · filed 2026-03-19 |
| 2023-12-31 | 10.70% 10-K · filed 2025-03-06 |
| 2022-12-31 | 10.60% 10-K · filed 2024-03-13 |
| 2021-12-31 | 11.90% 10-K · filed 2024-03-13 |
| 2020-12-31 | 12.60% 10-K · filed 2023-03-23 |
| 2019-12-31 | 12.50% 10-K · filed 2022-03-14 |
| 2019-09-30 | 12.40% 10-Q · filed 2019-11-12 |
| 2019-06-30 | 12.30% 10-Q · filed 2019-08-14 |
| 2019-03-31 | 12.30% 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |